672 related articles for article (PubMed ID: 17602081)
1. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Maki RG; Wathen JK; Patel SR; Priebat DA; Okuno SH; Samuels B; Fanucchi M; Harmon DC; Schuetze SM; Reinke D; Thall PF; Benjamin RS; Baker LH; Hensley ML
J Clin Oncol; 2007 Jul; 25(19):2755-63. PubMed ID: 17602081
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
3. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Hensley ML
Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
5. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL; Chawla SP; Attia S; Schöffski P; Gelderblom H; Chmielowski B; Le Cesne A; Van Tine BA; Trent JC; Patel S; Wagner AJ; Chugh R; Heyburn JW; Weil SC; Wang W; Viele K; Maki RG
Cancer; 2019 Jul; 125(14):2445-2454. PubMed ID: 31034598
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
[TBL] [Abstract][Full Text] [Related]
10. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
[TBL] [Abstract][Full Text] [Related]
12. [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Bay JO; Cabrespine A; Gilliot O; Bailly C; Vincent C; Mishellany F; Gimbergues P
Bull Cancer; 2007; 94 Spec No Actualites():S122-6. PubMed ID: 17845981
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
[TBL] [Abstract][Full Text] [Related]
14. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.
Kuo C; Kent PM; Logan AD; Tamulonis KB; Dalton KL; Batus M; Fernandez K; Mcfall RE
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221727
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Mora J; Cruz CO; Parareda A; de Torres C
J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Kataoka K; Tanaka K; Mizusawa J; Kimura A; Hiraga H; Kawai A; Matsunobu T; Matsumine A; Araki N; Oda Y; Fukuda H; Iwamoto Y;
Jpn J Clin Oncol; 2014 Aug; 44(8):765-9. PubMed ID: 24916336
[TBL] [Abstract][Full Text] [Related]
20. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Leu KM; Ostruszka LJ; Shewach D; Zalupski M; Sondak V; Biermann JS; Lee JS; Couwlier C; Palazzolo K; Baker LH
J Clin Oncol; 2004 May; 22(9):1706-12. PubMed ID: 15117993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
